Scancell Share Discussion Threads

[inanaco] 18/7/2024 20:18

CheckMate 067 Nivo/Ipi 314 patients 22% complete response

this is the next Data of interest

above 10 patients with CR after two years

[inanaco] 18/7/2024 20:08

as explained before its the efficacy that makes these trials so compelling it means predicting a phase 3 trial is so easy ... because your exceeding what you need for approval

you could have a 15% error and still get approval

[inanaco] 18/7/2024 20:06

they have not split the Iscib1 trial into two ... so i dont know if they will report at 16 or not or wait for 27 out of 43

[chilltime] 18/7/2024 20:02

Inan

Clarifying the post.

27 hit is the target to justify moving forward to the next phase, mentioned as 90% probability, so once 27 is hit it should become instant price sensitive news, with the Scib phase 2 ending there.

So that news could be any day. 30 mentioned, so 90% needed to hit 27.

Iscib, they would probably want to see a similar number of confirmed scans to scib (week 19).
So perhaps 15 or so post week 19, or as they have done before, post week 13 with the words subject to a confirmatory scan.

Either way it’s a very exciting time ahead.

As a reminder it’s about 8 months since the Scib second data. It’s flown by and likely material updates in the next 3 months.

How much further is it, first one to see the sea game, is approaching🙌

[marcusl2] 18/7/2024 16:53

As is often the case with big pharma pipelines, so many of the key assets are in-licensed, sometimes from other pharma companies, as we saw with the massive $22B Merck / Daiichi deal (Merck has generally been the most aggressive with BD in this space)

[inanaco] 18/7/2024 10:35

Lindy can calculate the response rate at any time with current Data known, but not relevant to the trial endpoints which requires the 27 ORR responders thus not requiring RNS, but gives credibility to "Going well" and "new Board members"

[markingtime] 18/7/2024 10:11

That iSCIB number of ten in now about three months old. Since it was recruiting fast in April/May it should be much higher now. I wonder if the initial iSCIB assessments are what underpins Lindy's interview confidence.

[chilltime] 18/7/2024 08:37

Looking back at comments on rivalry between Merck and BMS re melanoma in 2018.

Both are now listed as top revenue loss risk due to patent cliffs. The raved about results don’t seem that impressive 75% v 61% (placebo).

As in recent personalised Melanoma vaccine trials, it seems to be more about minor gain trading blows via the media than step change big gains like Scib is demonstrating.

Fast forward to 2024 with Scancell looking like the potential head and shoulders lead in the market on something they both crave.

2018 article.

Merck needed a big win in melanoma to help it try to catch up to archrival Bristol-Myers Squibb. And over the weekend, it got one.

At the American Association for Cancer Research annual meeting Sunday, the New Jersey drugmaker rolled out results showing that in postsurgery patients, Keytruda cut the risk of disease recurrence or death—leading to progression-free survival in those patients—by 43% compared with placebo.



At the one-year mark, 75.4% of Keytruda patients hadn’t seen their disease return, while just 61% of patients on placebo could say the same. And in those with PD-L1-positive tumors, Keytruda’s benefit was even more pronounced, paring down the recurrence risk by 46%.

Roy Baynes, Merck’s head of global clinical development, in a statement called the data “compelling221; and added that they “mark an important advancement for the treatment of resected stage 3 melanoma.”

Now, Merck will wait for word from regulators around the world—and if it gets its green lights, it’ll head into battle with Bristol and its own immuno-oncology contender Opdivo. That drug snagged its adjuvant go-ahead in late December after a speedy review at the FDA.

[chilltime] 18/7/2024 07:12

The volume over this last week so is at odds with typical Scancell trading levels, suggesting a new buyer or buyers.

No doubt some stock from those in and out has been acquired.

Scib 30 known, and iscib, 10 known should all have scan data by the end of this quarter, but obviously Scancell have the growing data as each scan drops in.

Modi combo progress too.

The only hints we have is Lindy repeatedly restating 85% on Scib (declared news) so it’s maintaining that level or higher.

On everything else she looks confident with a cracked it comment.

Also comments about Genmab potential milestone payments, which was absent before. She has said things are going well there but couldn’t give data. Going into phase 1 seems to be the most likely first milestone payment.

All is looking very good for when the various news eventually drops.

[inanaco] 17/7/2024 13:23

bit slow today, but a rising bid , maybe a bigger order to come

[sci102] 17/7/2024 11:29

And I don't get the need to get the "pub experience" (often the "football fan club" experience) in forums where people should care about their capital and profit.

[rogerbridge] 16/7/2024 22:46

Strapped in ready and waiting to fly.

[ruckrover] 16/7/2024 22:16

>Are we rich yet?

[marcusl2] 16/7/2024 20:59

MIDAS SHARE TIPS unearths companies working on future blockbuster treatments
10 July 2024



Scancell
Britain is widely recognised as a healthcare powerhouse with firms champing at the bit to produce blockbuster sales.

Many are in the cancer field. Despite the hype around Ozempic, the market for cancer drugs is at least three times bigger than its weight-loss counterpart and expected to remain so for years.

Already generating sales of almost £175billion a year, revenues from cancer treatments are forecast to more than double this decade and carry on rising thereafter.

That leaves room for plenty of blockbusters and Scancell is hoping to create one of them.

Founded by immunologist Professor Lindy Durrant, the company is developing a cure for advanced skin cancer and early signs are highly encouraging.

The treatment combines a vaccine developed by Durrant and her team with two widely available drugs. Trials to date have shown an 85 per cent success rate, far outweighing alternative approaches and better than Durrant ever imagined.

Vaccines are usually associated with disease prevention, from smallpox to measles to Covid.

Cancer vaccines are different. They aim to stimulate the body's immune system so that it produces cells that will fight and destroy cancer tumours.

Researchers have been trying to develop an effective vaccine for years but cancer keeps outwitting them.

Durrant's Eureka moment came when she decided to try a combination approach, blending her immune-system-boosting vaccine with drugs that allow the medicine to enter tumorous cells and do their magic.

The treatment has already proved successful on a small group of patients. A larger trial will be ready by the end of this year and further studies are expected thereafter.

Drug trials can take years but Durrant should be able to move faster, as her treatment could prove a lifesaver. There is also the possibility of moving into other forms of cancer, which could help millions of people worldwide.

Existing cancer treatments tend to be extremely expensive, riddled with side-effects or both. Scancell's therapy is simple to make, easier on the body than alternatives and a lot cheaper too.

Midas verdict: Scancell shares, which are listed on the junior AIM market, are less than 12p today. The company has been through tough times and nothing is certain in the world of drug research. But Durrant has more than 40 years' experience in the cancer field. She is a renowned professor at Nottingham University and believes she is on to a winner. If she is right, Scancell could fly - and that makes the shares well worth considering.

[moljen] 16/7/2024 18:33

Are we rich yet?

Interesting 12 months ahead, fairly sure said that 12 months ago though. Lets hope this time we stay above my long time average as counted chickens too soon last time!

[the real lozan] 16/7/2024 16:18

"dress code"
Could there be ANY better xample of the difference between my world and that of the Dis maid's world ???

[inanaco] 16/7/2024 16:06

your garden does not have a lawn then Lozan .... ?

or is the lack of your own mobility the cause of the great upkept

similar to your dress code

[inanaco] 16/7/2024 16:05

Clinical trial characteristics

Clinical trials enrolled a median of 187 (interquartile range 97-424) patients for orphan indications compared with 521 (219-793; P<0.001) patients for non-orphan indications. Median trial size was 521, 286, 199, and 85 patients for non-orphan and common, rare, and ultra-rare orphan indications (P<0.001). Orphan indications were less often supported by concurrent randomized controlled trials (52% v 76%; P<0.001) of phase 3 design (51% v 73%; P<0.001). The share of double blind (32% v 33% v 20% v 4%; P=0.002) concurrent randomized controlled trials (76% v 59% v 54% v 16%; P<0.001) of phase 3 design (73% v 55% v 54% v 12%; P<0.001) diminished from non-orphan to common, rare, and ultra-rare orphan indications, respectively. Concurrent randomized controlled trials for orphan indications less often included an assessment of overall survival (85% v 66%; P<0.001). Temporal differences in the FDA approval of orphan cancer drug indications are shown in supplementary table D

[inanaco] 16/7/2024 15:50

value above inflation



SCIB1 has Orphan Status

[inanaco] 16/7/2024 15:47

look at Fig 4

Objective response rates across thousands of patients and hundreds of trials

what do u see ........... Max about 60%

this is why 85% is astonishing .........

wake up

[inanaco] 16/7/2024 14:55

in France

nothing is simple

[inanaco] 16/7/2024 14:51

Inheritance Tax Rates in Thailand
Tax Threshold: Inheritance tax is applicable only if the estate’s value exceeds 100 million Baht (approximately $3 million USD).

work the system